1-5 of 5
Nancy A. Dawson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Available to Purchase
Debashis Sarker, Nancy A. Dawson, Ana M. Aparicio, Tanya B. Dorff, Allan J. Pantuck, Ulka N. Vaishampayan, Lynn Henson, Lakshmi Vasist, Sumita Roy-Ghanta, Michele Gorczyca, Whitney York, Gopinath Ganji, Jerry Tolson, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5248–5257.
https://doi.org/10.1158/1078-0432.CCR-21-1115
Published: 01 October 2021
View articletitled, A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

Free
Michael B. Atkins, F. Stephen Hodi, John A. Thompson, David F. McDermott, Wen-Jen Hwu, Donald P. Lawrence, Nancy A. Dawson, Deborah J. Wong, Shailender Bhatia, Marihella James, Lokesh Jain, Seth Robey, Xinxin Shu, Blanca Homet Moreno, Rodolfo F. Perini, Toni K. Choueiri, Antoni Ribas
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (8): 1805–1815.
https://doi.org/10.1158/1078-0432.CCR-17-3436
Published: 12 April 2018
View articletitled, Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Open the PDF for Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma

Free
Nancy A. Dawson, Chuanfo Guo, Richard Zak, Brenda Dorsey, Jeanne Smoot, Jade Wong, Arif Hussain
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (23): 7812–7819.
https://doi.org/10.1158/1078-0432.CCR-04-0310
Published: 07 December 2004
View articletitled, A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma
Open the PDF for A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma in another window
Journal Articles

Importance of Serum Hemoglobin in Hormone Refractory Prostate Cancer

Free
Robin T. Vollmer, Philip W. Kantoff, Nancy A. Dawson, Nicholas J. Vogelzang
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (4): 1049–1053.
Published: 01 April 2002
View articletitled, Importance of Serum Hemoglobin in Hormone Refractory Prostate Cancer
Open the PDF for Importance of Serum Hemoglobin in Hormone Refractory Prostate Cancer in another window
Journal Articles

A Prognostic Score for Hormone-Refractory Prostate Cancer: Analysis of Two Cancer and Leukemia Group B Studies

Free
Robin T. Vollmer, Philip W. Kantoff, Nancy A. Dawson, Nicholas J. Vogelzang
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (4): 831–837.
Published: 01 April 1999
View articletitled, A Prognostic Score for Hormone-Refractory Prostate Cancer: Analysis of Two Cancer and Leukemia Group B Studies
Open the PDF for A Prognostic Score for Hormone-Refractory Prostate Cancer: Analysis of Two Cancer and Leukemia Group B Studies in another window